Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)
Northland Securities analyst Carl Byrnes maintained a Buy rating for MiMedx Group (MDXG) with a price target of $12.00. Byrnes, who focuses on the Healthcare sector, has an average return of -4.1% and a 36.78% success rate. MiMedx Group also received a Buy rating from TR | OpenAI – 4o’s Dex Genotek, while a Hold rating was reiterated by TR | OpenAI – 4o on October 30.
Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group today and set a price target of $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Byrnes covers the Healthcare sector, focusing on stocks such as Alvotech, Brainsway, and BioLife Solutions. According to TipRanks, Byrnes has an average return of -4.1% and a 36.78% success rate on recommended stocks.
In addition to Northland Securities, MiMedx Group also received a Buy from TR | OpenAI – 4o’s Dex Genotek in a report issued yesterday. However, on October 30, TR | OpenAI – 4o reiterated a Hold rating on MiMedx Group (NASDAQ: MDXG).
